Santen Pharmaceutical Co., Ltd. (SNPHY)

Market Cap	3.47B
Revenue (ttm)	2.00B
Net Income (ttm)	242.11M
Shares Out	n/a
EPS (ttm)	0.69
PE Ratio	14.34
Forward PE	n/a
Dividend	0.25 (2.43%)
Ex-Dividend Date	Mar 28, 2025

Volume	5,020
Average Volume	7,776
Open	10.32
Previous Close	9.96
Day's Range	9.92 - 10.71
52-Week Range	8.65 - 13.00
Beta	0.20
RSI	50.49
Earnings Date	May 13, 2025

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2α derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension. The company also offers sepetaprost, a prostaglandin analogue eye drop drug that is in pha...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1890
• Employees: 3,744
• Stock Exchange: OTCMKTS
• Ticker Symbol: SNPHY

Financial Performance

In 2024, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.26 billion, an increase of 36.13%.

Financial numbers in JPY